Humacology Transdermal CBD CBG Cream Advanced Formula Specialty Dual Action

Humacology Transdermal CBD CBG Cream

Humacology Transdermal CBD CBG Cream is an advanced specialty topical designed for prescribed patients who want a targeted, dual-action cannabinoid product delivered through the skin rather than through inhalation or oral administration. Formulated with both cannabidiol and cannabigerol, this cream is developed to support localised therapeutic outcomes through a transdermal delivery mechanism that allows active cannabinoids to penetrate beyond the outer skin layer and interact with receptors in the underlying tissue. As a dual-action formula, it combines two distinct cannabinoids with potentially complementary therapeutic profiles, giving patients and prescribers a more nuanced tool within a broader treatment plan.

This transdermal approach matters for patients who are managing localised discomfort or conditions that may benefit from direct topical cannabinoid application, or for those who prefer to avoid inhalation as their primary route of administration. Humacology has developed this formula with pharmaceutical-grade precision, focusing on skin penetration technology that maximises the bioavailability of both CBD and CBG at the site of application rather than simply coating the surface. For many patients, this cream represents a meaningful addition to their existing treatment protocol rather than a standalone replacement.

Humacology positions this product within its specialty formulation range, distinct from standard topicals, and it is produced to support consistent ongoing availability for prescribed patients. Those who have been directed toward transdermal cannabinoid therapy by their prescriber are encouraged to order promptly to maintain continuity in their treatment routine.

CBD content

Each batch of Humacology Transdermal CBD CBG Cream is tested by an independent laboratory, and the certificate of analysis reports total CBD content per unit specific to that production run. CBD is the primary active cannabinoid in this formulation, selected for its well-documented interaction with the endocannabinoid system and its profile as a non-intoxicating therapeutic compound suited to topical delivery.

The transdermal delivery mechanism is designed to support consistent CBD absorption through the skin at the application site, and patients should always refer to their batch-specific COA and prescriber guidance rather than general marketing figures when determining appropriate usage.

Patients who have questions about the CBD content of their specific batch or about how this formulation compares to other CBD products in the Little Green Pharma range should raise these with their prescribing doctor or pharmacist before adjusting their application routine.

Therapeutic Goods Administration cannabis guidance

CBG content

Alongside CBD, each unit of Humacology Transdermal CBD CBG Cream contains a defined quantity of cannabigerol, reported on the batch-specific certificate of analysis. CBG is sometimes referred to as the precursor cannabinoid and has attracted growing scientific interest for its distinct interaction profile within the endocannabinoid system, separate from the pathways more commonly associated with CBD.

The inclusion of CBG alongside CBD is the defining dual-action characteristic of this formulation, and Humacology has calibrated the ratio of the two cannabinoids specifically to support their complementary interaction at the tissue level when delivered transdermally. Patients should review the COA for their specific batch to understand the exact CBG concentration in their product.

The quality team tests for both CBD and CBG on every production run to ensure the full cannabinoid picture is available to prescribing doctors and patients, supporting informed decisions about whether this dual-action ratio is appropriate for a given patient’s treatment goals.

Dual action formula

The advanced dual-action formulation of this cream is what sets it apart from single-cannabinoid topicals within the medical cannabis range. By combining CBD and CBG within a single transdermal base, Humacology has developed a product that delivers two distinct cannabinoid interactions at the site of application simultaneously, rather than relying on a single active compound alone.

This dual-action approach reflects an understanding of the entourage effect principle, where cannabinoids may work more effectively in combination than in isolation, applied specifically to a topical context. Humacology’s formulation team has developed the CBD and CBG ratio in this cream with this interaction in mind, aiming to produce a product that goes beyond a simple cannabinoid extract applied to a standard cream base.

Patients and prescribers considering this product as part of a broader treatment plan should discuss how the dual-action cannabinoid profile fits alongside any other cannabis products currently being used, to ensure the overall cannabinoid load across all administration routes is appropriate.

Transdermal delivery mechanism

The transdermal delivery mechanism used in this cream is what distinguishes it from a standard topical product. Rather than simply providing surface-level relief, the formulation is designed to carry active cannabinoids through the outer skin barrier and into the underlying tissue layers, where they can interact with local endocannabinoid receptors more directly.

This penetration technology involves a carefully developed excipient base that supports skin permeation without causing irritation, allowing CBD and CBG to be absorbed at a deeper level than conventional creams or ointments. The result is a more targeted delivery of active cannabinoids to the tissues directly beneath the application site.

Patients should apply the cream as directed by their prescriber, focusing on the specific area of the body identified for treatment, and should avoid applying it to broken or irritated skin without first seeking medical advice.

NCBI research on transdermal cannabinoid delivery

Ingredients and formulation

The active ingredients in Humacology Transdermal CBD CBG Cream are pharmaceutical-grade CBD and CBG, supported by an excipient base formulated to maximise transdermal absorption. Humacology sources its active cannabinoid ingredients to pharmaceutical standards, ensuring that what is listed on the label and certificate of analysis accurately reflects what is present in each tube.

The supporting ingredients in the base are selected for skin compatibility and penetration-enhancing properties, with formulation decisions made in the context of a medical product intended for prescribed patient use rather than a general cosmetic application. Patients with known skin sensitivities or allergies should review the full ingredient list with their pharmacist before first use.

Batch-to-batch consistency in both the active cannabinoid concentrations and the excipient base is maintained through standardised production protocols and confirmed through independent laboratory testing prior to release.

Batch testing

Every production run of Humacology Transdermal CBD CBG Cream undergoes independent laboratory testing prior to release, covering active cannabinoid potency for both CBD and CBG, and screening for contaminants including microbials, heavy metals, and any residual processing solvents. This testing regime is a core part of Little Green Pharma’s quality assurance process and applies equally to specialty topical formulations as to any other product in the range.

Results are documented in a certificate of analysis that is batch-specific, meaning the figures correspond exactly to the tube a patient receives rather than an average across multiple production runs. This traceability is particularly important for a topical cannabinoid product, where consistent active ingredient concentration directly affects the reliability of the therapeutic outcome at the application site.

Patients are encouraged to request or review their batch’s COA and raise any questions about testing results with their prescribing doctor or pharmacist before beginning or adjusting their application routine.

How to use and application guidance

Humacology Transdermal CBD CBG Cream is intended for external use only and should be applied to clean, unbroken skin at the site directed by the prescribing doctor. Patients should use the amount specified in their prescription or as directed by their pharmacist, and should avoid contact with eyes, mucous membranes, or open wounds.

The transdermal absorption process means the active cannabinoids in this cream require some time to penetrate the skin barrier after application, and patients should allow adequate time after applying before assessing the effect at the treatment site. Washing the application area immediately after use may reduce absorption.

As with all prescription medical cannabis products, patients should not adjust their application frequency or amount without first consulting their prescriber, and should report any skin reactions or unexpected effects to their doctor promptly.

Packaging freshness seal

Humacology Transdermal CBD CBG Cream is packaged in a sealed pharmaceutical-grade tube fitted with a tamper-evident closure, designed to protect the formulation from contamination, oxidation, and degradation during transit and storage. This packaging approach preserves the integrity of the active CBD and CBG content from the point of manufacture through to the patient’s first application.

The tamper-evident closure provides assurance that the product has not been accessed or compromised between leaving the dispensing pharmacy and arriving at the patient’s door, which is particularly important for a topical formulation whose active ingredient stability depends on the packaging remaining intact.

Patients should store the tube in a cool, dry place away from direct sunlight and heat, and should ensure the cap is firmly replaced after each use to preserve the remaining product.

Shipping, insurance, and delivery assurance

All orders are covered by insured freight, meaning the value of the shipment is protected in the event of loss or damage during transit, giving patients confidence that their prescribed treatment is financially safeguarded from dispatch to doorstep. Given the prescription nature of this product, deliveries require a signature on delivery, ensuring the package is received directly by the patient or an authorised recipient.

Before any order leaves the dispensing facility, it passes through pre-shipment quality checks, which confirm that packaging seals are intact, labelling is correct, and the product matches the prescription on file. This step exists specifically to catch any issues before they reach the patient.

In the rare event that an issue does occur, a clear damage claim process is available. Patients should photograph the affected packaging and product immediately upon receipt and contact customer support within the stated claim window so the matter can be assessed and resolved promptly.

To explore further topical and specialty cannabinoid products available for prescribed patients, browse the full topical creams and gels collection 

Frequently Asked Questions